WHO’s Low‑Cost Plan: A $10 Antiviral to Save the World (and Your Wallet)

In Brussels, a WHO‑led initiative is on a mission: make Covid‑19 treatment affordable for low‑income countries. A draft Accurate Access to Covid‑19 Tools Accelerator (ACT‑A) says drugs could run as low as $10 (≈S$13.40) per course. And that’s not just a poetic figure—Merck’s experimental pill Molnupiravir is likely to be one of the stars.

What the Plan Actually Outlines

• Deliver ≈1 billion rapid tests to poorer nations.
• Provide ~120 million antiviral courses for mild cases, out of an anticipated 200 million new infections over the next year.
• Keep the costs low after the “vaccine race” left the world’s poorest countries with a measly supply.

Getting the Figures Right

The draft wants an extra $22.8 billion (≈S$30.8 billion) until September 2022 to purchase and transport vaccines, drugs, and tests. Donors have already pledged $18.5 billion. The difference will jack the supply gaps between rich and poorer nations.

Molnupiravir: The Middle‑Country Hero?

Even though the draft doesn’t list the drug outright, it implies the $10 price point applies to “novel oral antivirals for mild/moderate patients.” Molnupiravir, the only pill in late‑stage trials that’s shown promise so far, is the likely candidate.

In the U.S., the agency has agreed to pay $700 per course for 1.7 million courses— a staggering 70‑times more than the world plan. Meanwhile, Harvard’s research suggests a generic version could go down to $7.7 under optimized production, with a realistic price target of $20.

The WHO is already talking to Merck and eight Indian generics firms to lock in supply by the end of November, aiming for rollout in Q1 2023.

More Meds on the Table

• Up to 28 million treatment courses slated for high‑risk mild/moderate patients, secured under advance purchase agreements.
• Later phases may bring in additional oral antivirals.
• Repurposed pills for critical patients: 4.3 million courses at $28 each (though no specific drug name is mentioned).
• Oxygen supply pledged for 6‑8 million severe cases by September 2022.

Before the G20 Summit

A spokesperson for ACT‑A says the document (dated Oct 13) is still a draft and will be sent to global leaders ahead of a G20 summit in Rome. No comment will be made until it’s finalized.

Bottom line: WHO’s plan is all about making Covid treatment affordable and accessible to the most vulnerable. With a $10 antiviral on the table, not only could we jumpstart the recovery in poorer nations, but we could also see a global team throw a celebratory “hooray” at a pandemic that finally gets contained.

Tests

Boosting Covid Diagnostics in Low‑Income Nations

Got a big deal on hand? That’s what the ACT‑A programme thinks it has. They’re planning to pour a whopping $22.8 billion into Covid‑19 tests and aim to double the testing reach in the world’s poorest countries.

Where the Money Goes

Think of the budget like a gigantic pie: about one‑third is earmarked for diagnostics, and that slice is the largest of any expense. The rest will go to other essentials like vaccines and logistics.

Current Testing Reality

• In low‑income and lower‑middle‑income countries, only about 50 tests per 100,000 people daily are happening.
• Astonishingly, richer nations run around 750 tests per 100,000.
• ACT‑A wants to bump that to at least 100 tests per 100,000 in the poorer states.